AZ-4217: A high potency BACE inhibitor displaying acute central efficacy in different In vivo models and reduced amyloid deposition in Tg2576 mice

Journal of Neuroscience

Volumn 33, Issue 24, 2013, Pages 10075-10084

  Eketjäll, Susanna ^a,b   Janson, Juliette ^a   Jeppsson, Fredrik ^a   Svanhagen, Alexander ^a   Kolmodin, Karin ^a   Gustavsson, Susanne ^a   Radesäter, Ann Cathrin ^a   Eliason, Kristina ^a   Briem, Sveinn ^a   Appelkvist, Paulina ^a   Niva, Camilla ^a   Berg, Anna Lena ^a   Karlström, Sofia ^a   Swahn, Britt Marie ^a   Fälting, Johanna ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AZ 4217; BETA SECRETASE INHIBITOR; CATHEPSIN D; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; ENZYME BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GUINEA PIG; IC 50; IMMUNOASSAY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; FEMALE; GUINEA PIGS; HUMANS; ISOINDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEURONS; PEPTIDE FRAGMENTS; PYRIDONES; TIME FACTORS;

EID: 84878823099     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1165-13.2013     Document Type: Article

References (37)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377:1019-1031. CrossRef Medline
2. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Bowes Rickman C, Golde T, Grant MB, Saftig P, Serneels L, de strooper B, Joussen AM, Boulton ME (2012) β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 4:980-991. CrossRef Medline
3. Cao L, Rickenbacher GT, Rodriguez S, Moulia TW, Albers MW (2012) The precision of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease. Sci Rep 2:231. Medline
4. Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J (2011) β-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J 25:775-784. CrossRef Medline
5. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo- Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360:672-674. CrossRef Medline
6. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21: 457-478. CrossRef Medline
7. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, Troutman MD, Liston TE (2011) Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39:1270-1277. CrossRef Medline
8. D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A (2012) Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Discov 7:19-37. CrossRef Medline
9. Forman M., Palcza J, Tseng J, Leempoels J, Ramael S, Han D, Jhee S, Ereshefsky L, Tanen M, Laterza O, Dockendorf M, Krishna G, Ma L, Wagner J, Troyer M (2012) The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Ab peptides in healthy subjects following singleand multiple-dose administration. ICAD conference abstract. Alzheimers Dement 8:704. CrossRef
10. Fridén M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2009) Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 37:1226-1233. CrossRef Medline
11. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Aβ pathology and behavioral deficits in a mouse model of Alzheimer's Disease. J Neurosci 30:11157-11166. CrossRef Medline
12. Funato H, Yoshimura M, Kusui K, Tamaoka A, Ishikawa K, Ohkoshi N, Namekata K, Okeda R, Ihara Y (1998) Quantitation of amyloid betaprotein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol 152:1633-1640. Medline
13. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356. CrossRef Medline
14. Hartz AM, Miller DS, Bauer B (2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 77:715-723. CrossRef Medline
15. Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ (2011) Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci 31:15861-15869. CrossRef Medline
16. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102. CrossRef Medline
17. Huang H, La DS, Cheng AC, Whittington DA, Patel VF, Chen K, Dineen TA, Epstein O, Graceffa R, Hickman D, Kiang YH, Louie S, Luo Y, Wahl RC, Wen PH, Wood S, Fremeau RT Jr (2012) Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease. J Med Chem 55:9156-9169. CrossRef Medline
18. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9:1520-1525. CrossRef Medline
19. Jeppsson F, Eketjäll S, Janson J, Karlström S, Gustavsson S, Olsson LL, Radesäter AC, Ploeger B, Cebers G, Kolmodin K, Swahn BM, von Berg S, Bueters T, Fälting J (2012) J Biol Chem 287:41245-41257.
20. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488:96-99. CrossRef Medline
21. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381. Medline
22. Kim DY, Gersbacher MT, Inquimbert P, Kovacs DM (2011) Reduced sodium channel Na(v)1.1 levels in BACE1-null mice. J Biol Chem 286: 8106-8116. CrossRef Medline
23. Lai R, Albala B, Kaplow JM, Aluri J, Yen M, Satlin A (2012) First-in human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma β-amyloid levels after single dosing. Alzheimer Dement 8:96. CrossRef
24. Malamas MS, Robichaud A, Erdei J, Quagliato D, Solvibile W, Zhou P, Morris K, Turner J, Wagner E, Fan K, Olland A, Jacobsen S, Reinhart P, Riddell D, Pangalos M (2010) Design and synthesis of aminohydantoins as potent and selective humanβ-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg Med Chem Lett 20:6597-6605. CrossRef Medline
25. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS betaamyloid in Alzheimer's disease. Science 330:1774. CrossRef Medline
26. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, et al. (2011) Robust Central. Reduction of amyloid-b in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31:16507-16516. CrossRef Medline
27. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S (2007) Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem 282: 26326-26334. CrossRef Medline
28. Probst G, Xu YZ (2012) Small-molecule BACE1 inhibitors: a patent literature review (2006-2011). Expert Opin Ther Pat 22:511-540. CrossRef Medline
29. Pype S, Moechars D, Dillen L, Mercken M (2003) Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J Neurochem 84:602-609. CrossRef Medline
30. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, et al. (2001) BACE knock-out mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10:1317-1324. CrossRef Medline
31. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. (2009) First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 Inhibitor in nonhuman primates. J Pharmacol Exp Ther 328:131-140. CrossRef Medline
32. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Wu G, Crouthamel M, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, Jin L, Ellis J, Holloway MK, Munshi S, Allison T, Hazuda D, Simon AJ, Graham SL, Vacca JP (2006) Macrocyclic inhibitors of β-secretase: functional activity in an animal model. J Med Chem 49:6147-6150. CrossRef Medline
33. Swahn BM, Kolmodin K, Karlström S, von Berg S, Söderman P, Holenz J, Berg S, Lindström J, Sundström M, Turek D, Kihlström J, Slivo C, Andersson L, Pyring D, Rotticci D, Öhberg L, Kers A, Bogar K, Bergh M, Olsson L, et al. (2012) Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides. J Med Chem 55:9346-9361. CrossRef Medline
34. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741. CrossRef Medline
35. Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29:12787-12794. CrossRef Medline
36. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the β-secretase BACE1. Science 314:664-666. CrossRef Medline
37. Xia W, Wong ST, Hanlon E, Morin P (2012) γ-Secretase modulator in Alzheimer's disease: shifting the end. J Alzheimers Dis 31:685-696. Medline